|
End-of-day quote
Nasdaq
|
||
| - USD | - |
|
| 11-10 | Cellectar Biosciences, Inc., Q3 2026 Earnings Call, Nov 10, 2026 | |
| 11-10 | Cellectar Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026 | CI |
| Market Cap | 8M 7.29M 6.72M 6.11M 11.46M 741M 12.04M 81.73M 32.48M 405M 30.02M 29.39M 1.27B | P/E 2026 * |
-0.35x | P/E 2027 * | -0.39x |
|---|---|---|---|---|---|
| Enterprise Value | 8M 7.29M 6.72M 6.11M 11.46M 741M 12.04M 81.73M 32.48M 405M 30.02M 29.39M 1.27B | EV / Sales 2026 * |
-
| EV / Sales 2027 * | 3.11x |
| Free-Float |
98.35% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Cellectar Biosciences Inc
| Manager | Title | Age | Since |
|---|---|---|---|
James Caruso
CEO | Chief Executive Officer | 67 | 15/06/2015 |
Chad Kolean
DFI | Director of Finance/CFO | 61 | 28/05/2014 |
Jarrod Longcor
COO | Chief Operating Officer | 53 | 23/02/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
John Neis
BRD | Director/Board Member | 57 | 01/02/2008 |
James Caruso
BRD | Director/Board Member | 67 | 15/06/2015 |
Douglas Swirsky
CHM | Chairman | 56 | 01/08/2017 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -0.30% | -6.68% | +27.12% | +127.32% | 1,200B | ||
| +1.25% | -5.35% | +32.65% | +78.98% | 651B | ||
| +0.94% | -2.99% | +21.13% | +106.30% | 506B | ||
| -0.60% | -1.95% | +25.73% | +67.00% | 377B | ||
| +0.69% | -9.50% | +36.78% | +30.83% | 330B | ||
| +0.41% | -4.70% | +24.18% | +50.18% | 288B | ||
| +0.81% | -4.08% | -2.95% | +31.59% | 272B | ||
| -0.15% | -6.45% | +29.06% | +65.76% | 236B | ||
| -0.06% | -0.98% | +31.42% | +122.83% | 206B | ||
| Average | +0.33% | -4.76% | +25.01% | +75.64% | 452B | |
| Weighted average by Cap. | +0.30% | -5.19% | +26.02% | +87.88% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | - | 2.58M 2.35M 2.16M 1.97M 3.69M 238M 3.88M 26.3M 10.45M 130M 9.66M 9.46M 409M |
| Net income | -30.16M -27.47M -25.31M -23.02M -43.19M -2.79B -45.39M -308M -122M -1.53B -113M -111M -4.79B | -41.9M -38.16M -35.17M -31.99M -60.01M -3.88B -63.07M -428M -170M -2.12B -157M -154M -6.65B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions
















